Grass & Birch Allergy Phase II Parallel Studies

About the Case Study

Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe and were run in parallel. With two different indications required, Grass Pollen Allergy and Birch Pollen Allergy, Pharm-Olam completed a comprehensive feasibility program and presented the findings to the sponsor for analysis and approval.

Once approved, Pharm-Olam committed to recruit the required patients within 4 months, while adhering to strict inclusion and exclusion criteria.  Pharm-Olam completed enrollment ahead of schedule for both studies.

Sites & Locations:
23 Sites distributed between Germany and Poland (Grass Pollen study)
21 sites in Czech Republic, Germany and Poland (Birch Pollen study)

Services Provided:

  • Feasibility & Site Solutions
  • Project Management
  • Clinical Operations & Trial Management
  • Data Management
  • Medical Affairs & Pharmacovigilance
  • Patient Engagement Services
  • Biostatistics
  • Medical Writing
  • Quality Assurance
Share this: